Nebenwirkungen · Iclusig
Iclusig 5 mg hard capsules · Abschnitt 4.8 · PDF-Seite 63
HOS-128577 · Präparat HOS-096579
Table 7 Adverse Reactions observed in newly diagnosed Ph+ ALL patients in PhALLCON Study – frequency reported by incidence of treatment emergent events Ponatinib in combination with reduced- System organ class Frequency intensity chemotherapy Adverse reactions Pneumonia Conjunctivitis Infections and infestations Common Sepsis Septic shock Neutropenic infection Thrombocytopenia Anemia Neutropenia Very common Febrile neutropenia Blood and lymphatic system Leukopenia disorders Leukocytosis Myelosuppression Lymphopenia Common Cytopenia Agranulocytosis Hypokalaemia Hyperglycaemia Very common Hypocalcaemia Hypophosphataemia Hyperuricaemia Metabolism and nutrition Decreased appetite disorders Hypertriglyceridaemia Hyponatraemia Common Hypoalbuminaemia Hypercholesterolaemia Dyslipidaemia Fluid retention Psychiatric disorders Very common Insomnia Headache Neuropathy peripheral Very common Paraesthesia Nervous system disorders Peripheral sensory neuropathy Dizziness Common Hypoaesthesia Common Conjunctival hemorrhage Eye disorders Uncommon Retinal vein occlusion
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-31T14:12:00Z · SHA-256 4867aa10684948b4c421d8ab4cf806af86df3e9279763348c485fe3b6e3627c4 · Passage 6e55501e5c7daf11573026f6f79af788277376f478f540bbcac3abd807cda772 · Zeichen 20653–23728 im Abschnitt